CD274 and esophageal cancer: The authors also found that pembrolizumab is also effective in patients with negative PD‐L1 expression and its effectiveness is not associated with histologic characteristics.28 KEYNOTE‐181 study,a phase III clinical trial,was aimed to evaluate pembrolizumab versus chemotherapy as second‐line therapy for advanced esophageal cancer.